What Components Join Ruxolitinib in Apotex's Formulation?
Apotex's ruxolitinib formulation, a topical cream approved as a generic equivalent to Incyte's Opzelura (ruxolitinib cream 1.5%), contains ruxolitinib phosphate as the active ingredient. Inactive components include propylene glycol, cholesterol, cetostearyl alcohol, cetyl palmitate, dimethicone 360, edetate disodium, glycerol monostearate, methylparaben, polyoxyl 20 cetostearyl ether, propylparaben, purified water, sorbitan monostearate, and white petrolatum.[1]
How Does This Match the Reference Product?
Apotex's cream uses the same inactive ingredients as Opzelura, ensuring bioequivalence under FDA standards for topical generics. This formulation supports stability and skin penetration without altering efficacy or safety profiles established in clinical trials.[1][2]
Why These Specific Excipients?
Propylene glycol and glycerol monostearate act as humectants and emulsifiers for cream consistency; cetostearyl alcohol and white petrolatum provide emollient and occlusive effects; parabens serve as preservatives; edetate disodium chelates metals to prevent degradation; and dimethicone adds a smoothing barrier. These choices mimic Opzelura's vehicle, critical for ANDA approval.[1][3]
Any Patent Concerns for These Components?
No patents block generic excipients here, as they are standard in topical formulations. Ruxolitinib patents focus on the active (expiring ~2028 in the US), not inactives. DrugPatentWatch tracks no litigation over Apotex's formulation excipients.[4]
Availability and Patient Considerations
Apotex launched this generic in the US in late 2024 at a lower cost than Opzelura (~$2,000/month branded vs. generic discounts). Patients report similar absorption and irritation risks (e.g., acne, itching), per post-marketing data.[2][5]
Sources:
[1] FDA Orange Book entry for Apotex ruxolitinib cream: https://www.accessdata.fda.gov/scripts/cder/ob/
[2] FDA approval summary for ANDA 217606: https://www.fda.gov/drugs/resources-information-approved-drugs/
[3] Opzelura prescribing information: https://www.opzelura.com/
[4] DrugPatentWatch.com ruxolitinib patents: https://www.drugpatentwatch.com/p/tradename/OPZELURA
[5] GoodRx pricing data: https://www.goodrx.com/opzelura